GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

Nature Medicine

Volumn 19, Issue 5, 2013, Pages 567-575

  Kim, Minsuk ^a   Platt, Mathew J ^b   Shibasaki, Tadao ^c   Quaggin, Susan E ^a   Backx, Peter H ^d   Seino, Susumu ^c   Simpson, Jeremy A ^b   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LIRAGLUTIDE; PHENYLEPHRINE;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HEART ATRIUM; HEART MUSCLE CELL; MALE; MOUSE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SYSTOLIC BLOOD PRESSURE; VASCULAR RING; VASODILATATION;

ANIMALS; AORTA; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CYCLIC GMP; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; GUANINE NUCLEOTIDE EXCHANGE FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATRIURETIC PEPTIDE, C-TYPE; PERFUSION; PROTEIN PRECURSORS; RECEPTORS, GLUCAGON; VASODILATION;

MUS;

EID: 84877317750     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3128     Document Type: Article

References (44)

1. Goldfne, A.B. Assessing the cardiovascular safety of diabetes therapies. N. Engl. J. Med. 359, 1092-1095 (2008).
2. Fonseca, V.A., Zinman, B., Nauck, M.A., Goldfne, A.B. & Plutzky, J. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am. J. Med. 123, S2-S10 (2010).
3. Sivertsen, J., Rosenmeier, J., Holst, J.J. & Vilsboll, T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9, 209-222 (2012).
4. Fonseca, V.A. Ongoing clinical trials evaluating the cardiovascular safety and effcacy of therapeutic approaches to diabetes mellitus. Am. J. Cardiol. 108, 52B-58B (2011).
5. Ussher, J.R. & Drucker, D.J. Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187-215 (2012).
6. Drucker, D.J. & Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006).
7. 36 amide and amylin on the pulmonary circulation of the rat. Regul. Pept. 102, 81-86 (2001).
8. Nyström, T. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, E1209-E1215 (2004).
9. Chai, W. et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61, 888-898 (2012).
10. Vilsbøll, T., Christensen, M., Junker, A.E., Knop, F.K. & Gluud, L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br. Med. J. 344, d7771 (2012).
11. Crajoinas, R.O. et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Renal Physiol. 301, F355-F363 (2011).
12. Hirata, K. et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem. Biophys. Res. Commun. 380, 44-49 (2009).
13. Yu, M. et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens. 21, 1125-1135 (2003).
14. Gutzwiller, J.P. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89, 3055-3061 (2004).
15. Ban, K. et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117, 2340-2350 (2008).
16. Drucker, D.J., Dritselis, A. & Kirkpatrick, P. Liraglutide. Nat. Rev. Drug Discov. 9, 267-268 (2010).
17. Scrocchi, L.A. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 2, 1254-1258 (1996).
18. Holtwick, R. et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc. Natl. Acad. Sci. USA 99, 7142-7147 (2002).
19. Winquist, R.J. et al. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc. Natl. Acad. Sci. USA 81, 7661-7664 (1984).
20. Moore-Morris, T. et al. Identifcation of potential pharmacological targets by analysis of the comprehensive G protein-coupled receptor repertoire in the four cardiac chambers. Mol. Pharmacol. 75, 1108-1116 (2009).
21. Drucker, D.J., Philippe, J., Mojsov, S., Chick, W.L. & Habener, J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 84, 3434-3438 (1987).
22. release in INS-1 pancreatic β-cells. J. Physiol. (Lond.) 536, 375-385 (2001).
23. Shibasaki, T. et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc. Natl. Acad. Sci. USA 104, 19333-19338 (2007).
24. Richards, A.M. et al. Effects of β-human atrial natriuretic peptide in essential hypertension. Hypertension 7, 812-817 (1985).
25. Carraro-Lacroix, L.R., Malnic, G. & Girardi, A.C. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am. J. Physiol. Renal Physiol. 297, F1647-F1655 (2009).
26. Kocinsky, H.S., Dynia, D.W., Wang, T. & Aronson, P.S. NHE3 phosphorylation at serines 552 and 605 does not directly affect NHE3 activity. Am. J. Physiol. Renal Physiol. 293, F212-F218 (2007).
27. Wei, Y. & Mojsov, S. Tissue-specifc expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358, 219-224 (1995).
28. /-mice. Endocrinology 154, 127-139 (2013).
29. Smrcka, A.V., Brown, J.H. & Holz, G.G. Role of phospholipase Cβ in physiological phosphoinositide signaling networks. Cell Signal. 24, 1333-1343 (2012).
30. Ballermann, B.J. A highly sensitive radioreceptor assay for atrial natriuretic peptide in rat plasma. Am. J. Physiol. 254, F159-F163 (1988).
31. Chattington, P.D. et al. Atrial natriuretic peptide in type 2 diabetes mellitus: response to a physiological mixed meal and relationship to renal function. Diabet. Med. 15, 375-379 (1998).
32. Noyan-Ashraf, M.H. et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975-983 (2009).
33. Lønborg, J. et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33, 1491-1499 (2012).
34. Padmanabhan, S., Newton-Cheh, C. & Dominiczak, A.F. Genetic basis of blood pressure and hypertension. Trends Genet. 28, 397-408 (2012).
35. Moro, C. et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J. 18, 908-910 (2004).
36. Birkenfeld, A.L. et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 57, 3199-3204 (2008).
37. Bordicchia, M. et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J. Clin. Invest. 122, 1022-1036 (2012).
38. Engeli, S. et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J. Clin. Invest. 122, 4675-4679 (2012).
39. Ropero, A.B. et al. The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic β-cell function. Endocrinology 151, 3665-3674 (2010).
40. Zhang, J. et al. Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ. Res. 107, 540-548 (2010).
41. Yamamoto, H. et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110, 43-52 (2002).
42. elevation in vascular smooth muscle cells from C57BL/6 mice. Acta Pharmacol. Sin. 30, 1488-1495 (2009).
43. Sambrano, G.R. et al. Navigating the signalling network in mouse cardiac myocytes. Nature 420, 712-714 (2002).
44. 3V mutation. J. Clin. Invest. 121, 1009-1025 (2011).